postoperative DVT chemoprophylaxis received enoxaparin 40 mg starting ≥6 hours postoperatively, per our institution's usual guidelines. The choice between receipt of postoperative VTE chemoprophylaxis or not was at the discretion of the treating surgeons. All hematomas and other complications were managed appropriately and documented.
PURPOSE:
Minimally invasive cosmetic procedures are very popular with over 17 million procedures occurring in 2017. 1 Botulinum toxin and injectable fillers are the 2 most popular procedures because they help patients achieve a younger, more attractive appearance. Numerous studies have indicated that patients and physicians alike are highly satisfied with the results of botulinum toxin and injectable fillers. However, it remains unclear how the public responds to individuals after they are treated with these procedures. This study intends to first identify if botulinum toxin and hyaluronic acid fillers impact the way the public perceives a patient and second measure the impact of the public's change in perception by assessing if the public would behave differently toward a patient after treatment with botulinum toxin and hyaluronic acid fillers.
METHODS:
A total of 40 patients were recruited for this Institutional Review Board-approved study. Eligible patients were over 18 years old and had not received any cosmetic procedures in the past year. Patients were divided into 2 treatment groups. One group received 1 syringe of Juvéderm applied to their lips, and the other group received 50 units of botulinum toxin applied to their glabella, forehead, and crows feet. Each patient answered a survey about their interactions with others before treatment and returned for follow-up in 1 week to take the same survey. Demographics and surgical history were recorded, and before and after photographs were taken. Photographs were used to create a crowdsourced survey which asked responded to assess patients on different personality traits and indicate how likely they would be to engage in a particular action with the patient.
RESULTS:
A total of 1,000 survey responses were received. On average, the public perceived patients as significantly more attractive, trustworthy, intelligent, youthful, naturally beautiful, and likeable following treatment with botulinum toxin and Juvéderm (P < 0.05 for all). The public was also more likely to invite patients to social events and ask the patient on a date following treatment with botulinum toxin and Juvéderm (P < 0.05 for all). There were not significant changes in the public's likelihood to hire a patient, ask them for help with a work project, or lend the patient money following either treatment. Patients also reported that they felt more likely to be asked on a date following both treatments.
CONCLUSIONS:
This study suggests that treatment with minimally invasive cosmetics such as botulinum toxin and Juvéderm may impact the way the public both perceives and interacts with patients. Patients may be perceived more favorably in many ways. However, minimally invasive procedures are unlikely to impact how individuals interact with patients in a professional capacity. 
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PURPOSE: Tetracycline family antibiotics have demonstrated utility as sclerosing agents for lymphatic malformations and other lesions of impaired fluid drainage, including conjunctival chemosis, eyelid festoons, and malar edema. [1] [2] [3] [4] [5] However, the timing of improvement and patient-reported subjective outcomes for esthetic use of doxycycline hyclate injections in treating lower eyelid festoons and malar edema is not well-reported. The purpose of this study was to evaluate subjective patient satisfaction and timing of improvement of cosmetically significant lower eyelid festoons and malar edema treated with direct, intralesional injections of doxycycline hyclate.
METHODS:
An Institutional Review Board-approved, retrospective review was performed. Inclusion criteria were patients with lower eyelid festoons and/or malar edema treated with direct, intralesional injection of doxycycline hyclate at a concentration of 10 mg/ml. Exclusion criteria were inadequate follow-up, alternate doxycycline concentration, or alternate intervention during the observation period. The primary outcome measure was patient self-reported improvement which was graded as percentage improvement at each visit. Additional data collected included injection volume, concentration, timing of repeat injections, and any subjective patient-reported complaints. Standard statistical calculations were performed.
RESULTS:
Twenty-seven treatment areas of 15 patients met inclusion criteria. Average length of final follow-up was 20 weeks (SD, 16 weeks; range, 4-56 weeks). Overall, 9 out of 15 patients subjectively reported complete resolution of their lower eyelid festoons or malar edema and 13 out of 15 patients reported improvement of ≥50%. The average final patient-reported subjective improvement was 80% (SD, 27%; range, 33%-100%). The average time to final subjective improvement in appearance was 16 weeks from initial injection (SD, 10 weeks; range, 4-44). The average number of injections performed per side was 1.4 (SD, 0.64 injections; range, 1-3 injections). When necessary, repeat injections were performed at an average of 16 weeks following prior injection (SD, 3 weeks; range, 12-20 weeks). Average initial injection volume was 0.64 ml (SD, 0.29 ml; range, 0.2-1). Average repeat injection volume was 0.54 ml (SD, 0.35 ml; range, 0.2-1.5 ml). Patient-reported complaints included burning sensation and pain at the time of injection, and transient bruising, edema, and erythema following the injection. No significant dermatologic or visual complications were reported during the documented follow-up period.
CONCLUSIONS:
Direct, intralesional injection of doxycycline hyclate at a concentration of 10 mg/ml subjectively improved the appearance of lower eyelid festoons and malar edema. On average, final improvement took approximately 16 weeks.
